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The ducts and lobules of the normal human mammary gland are
lined by 2 epithelial cell types, luminal and basal (myoepithelial)
cells. Previous work (Lakhani et al, 1999) has demonstrated that
LOH identified in invasive carcinoma is already present indepen-
dently in ‘normal’ luminal and myoepithelial cells. This argues for
a common precursor cell which must have acquired the genetic
alteration prior to differentiation into the 2 epithelial cell types. It
is intriguing therefore that myoepithelial cells transform so rarely,
and that myoepithelial cell carcinomas of the breast appear to be
so rare in clinical practice (Tavassoli, 1991; Damiani et al, 1997;
Foschini and Eusebi, 1998). References in the literature are gener-
ally composed of single case reports (Erlandson and Rosen, 1982;
Thorner et al, 1986; Eusebi et al, 1987; Accurso et al, 1990;
Desautels, 1990; Lakhani et al, 1995; Shiraishi et al, 1999). A
comparative genomic hybridization (CGH) study of 10 cases of
conventional myoepithelial cell carcinoma demonstrated that these
aggressive tumours are genetically different from invasive ductal
carcinoma-NST in having very few, but specific genetic alterations
(Jones et al, 2000). 
The contribution of myoepithelial cells to ‘ordinary’ ductal
carcinomas is unclear, and reports suggest that 2–18% of so-called
invasive ductal carcinomas-NST show focal or diffuse myoepithe-
lial cell differentiation immunohistochemically, using a range 
of markers including basal cell cytokeratins, actin, calponin,
caldesmone, S100 protein (Gusterson et al, 1982; Nagle et al,
1986; Dairkee et al, 1988; Guelstein et al, 1988; Gould et al, 1990;
Wetzels et al, 1991; Malzahn et al, 1998; Tsuda et al, 1999). A
recent study utilizing cDNA microarrays used a hierarchical clus-
tering method to group breast tumours according to their similarity
in patterns of gene expression, and found a ‘basal-like’ group
consisting of 15% of tumours analysed (Perou et al, 2000).
Tumours with a basal cell phenotype have been reported to have a
different metastatic pattern and prognosis (Tsuda et al, 2000) 
In the present study we aimed to study the molecular cytoge-
netic profile of invasive carcinomas exhibiting a basal/myoepithe-
lial phenotype by laser capture microdissection (LCM) and CGH,
and compare the data to that of pure myoepithelial cell carcinomas
and ‘ordinary’ invasive ductal carcinomas-NST in order to investi-
gate whether their immunohistochemical phenotype is reflected at
a molecular genetic level. 
MATERIALS AND METHODS 
91 cases of invasive ductal carcinomas-NST were chosen at
random from the files of the Histopathology Department, Uni-
versity College Hospital, London, UK. These were 6 grade I, 45
grade II, and 41 grade III according to the grading system used in
the UK Breast Screening Programme (NCGBSP, 1995). Sections
from formalin-fixed, paraffin-embedded tissues were stained
immunohistochemically for the luminal epithelial marker cytoker-
atin (CK) 19 and the basal cell keratin CK14. Those tumours (6
cases – 6.6%) showing a focal (one or more small areas of keratin
14-positive cells) or diffuse CK14 expression, together with a
consultation case sent to SRL, which was diffusely positive with
keratin 14, were selected and here defined as cases with basal cell
phenotype. 
These were further characterized immunohistochemically by
staining with calponin, caldesmone, smooth muscle actin (SMA),
and S100 protein which are markers of myoepithelial cells (Foschini
et al, 2000). Immunohistochemistry for oestrogen receptor (ER),
progesterone receptor (PR), p53 and c-erbB2 was also carried out on
all CK14-positive tumours and the age-matched controls. Hence a
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total of 7 cases (of a total of 92) with a basal cell phenotype were
studied (source and dilutions for all of the antibodies used are
reported in Table 1). 
All sections were dewaxed in xylene, taken to absolute alcohol
(74OP) and blocked for endogenous peroxidase with 3% hydrogen
peroxidase in methanol for 10 mins. Sections were rinsed in tap
water and subjected to the appropriate pre-treatments as in Table 1.
The sections were blocked in normal goat serum (1/10 in Tris
buffered saline) for 10 minutes and the primary antibodies were
applied for 1 hour. The primary antibodies were rinsed off in
0.05% Tween 20 in Tris buffered saline (TBS/Tween), developed
using Dako Duet/HRP system and visualized with DAB 
(Kem-em-Tec). 
The scoring system used for assessment of ER and PR was the
Quick Score method (Barnes et al, 1996). c-erbB2 was scored
according to the guidelines published by Ellis and co-workers
(Ellis et al, 2000). The p53 was scored positive if greater than 10%
of the cells showed strong nuclear staining. 
Cases exhibiting a basal cell phenotype, as well as age- and
grade-matched invasive ductal carcinoma NST showing no CK14
immunoreactivity, were analysed by comparative genomic hy-
bridization (CGH). Some of the tumours (4 cases) showing a basal
cell phenotype were heterogeneous in their staining in the sense
that areas containing numerous keratin 14-positive cells were
alternating with patches of negative cells and hence, in these cases,
CK14-positive and -negative areas were microdissected from the
same case. Formalin-fixed, paraffin-embedded sections were
microdissected using Laser Capture Microdissection (LCM) using
the PixCell II system (Arcturus, Mountain View, California). DNA
extraction and CGH analysis was carried out as described previ-
ously (Jones et al, 2000). Briefly, the DNA was extracted with
0.5 mg ml–1 proteinase K. Amplification and fluorescent labelling
of the DNA from microdissected tumour and normal tissue was
carried out by DOP-PCR in 2 rounds as previously published
(Wells et al, 1999) and hybridized to normal male metaphase
spreads (Vysis UK Ltd, Richmond, England) for 2–3 days at 37°C.
Metaphase chromosome preparations were captured using a Zeiss
Axioskop microscope, Photometrics (Munich, Germany)
KAF1400 CCD camera, and Vysis SmartCapture software. Image
analysis was performed using Vysis Quips CGH software.
Between 5 and 10 representative images of high quality hybridiza-
tions were analysed, and the results combined to produce an
average fluorescence ratio for each chromosome. Control experi-
ments were carried out using normal:normal (microdissected
normal lymph node) co-hybridizations, whose average red:green
ratio levels and 95% confidence intervals were used to set the
lower and upper limits for scoring losses and gains of genetic
material as 0.80–1.20. The comparison of the mean number of
changes between CK14 positive and CK14 negative was done
using a one-sided Student’s t-test. 
RESULTS 
The 7 tumours that stained positive for keratin CK14 by immuno-
histochemistry were from patients with an age range of 44 to 87
years. The tumours were large ranging from 1.5 to 10 cm (mean
3.7 cm). They displayed a combination of pushing and invasive
margins and were arranged in large sheets, solid nests or trabec-
ulae of round to polygonal cells showing round to ovoid irregular
nuclei with large nucleoli (Figure 1). Their cytoplasm was
eosinophilic without evidence of granularity. No glandular struc-
tures were evident and necrosis was a common feature (5 of 7
cases). Mitoses, including abnormal forms, exceeded 8 per 10
high power fields. There was a moderate to prominent lympho-
plasmacytic infiltrate at the borders of 5 out of 7 tumour. Therefore
all these lesions were included in the spectrum of grade III inva-
sive ductal carcinoma. 
Immunohistochemistry (Table 2) with keratin 14 antibody
stained more than 50% of cells in 3 of 7 tumours (cases 2, 3 and 6).
In the remaining 4 cases the same antibody decorated 10–20% of
cells. 2 cases were negative with keratin 19 while the other 5 were
positive. The keratin 14-positive tumours were also positive with
at least 2 other myoepithelial markers 4 cases stained with
calponin, all with caldesmon and 4 with smooth muscle actin and 6
with S100. ER, PR and c-erbB2 were negative in all cases. Anti-
P53 antibody stained greater than 10% of cells in 2 cases. In
contrast, of the 7 ‘control’ cases, 5 were negative for all other
myoepithelial markers. 2 cases showed focal or diffuse S100
positivity only, all other markers were negative. 2 were positive
for c-erbB2 and 3 for P53 protein. 5 cases were both ER- and PR-
positive. 
CGH was carried out on these cases both on CK14-positive and,
where applicable (4 cases), negative areas of the same tumour
(Table 3) as well as in the 7 totally keratin 14-negative matched
cases (Table 4). The CK14-positive areas of tumour, whether focal
or diffuse, showed relatively few alterations, with a mean DNA
copy number change of 3.0. Where there were focal CK14-
negative areas within the tumour, these samples showed some
overlap in genetic alterations with the CK14-positive areas of the
tumour, but with further alterations (mean – 6.0). The 7 age- and
grade-matched CK14-negative invasive ductal carcinomas-NST
showed a molecular cytogenetic profile by CGH consistent
with the extensive literature on such cases (mean – 8.3, Table 4).
The difference in mean DNA copy number changes between 
Table 1 Antibodies used for immunohistochemistry 
Antibody Manufacturer Source Dilution Pre-treatment 
CK14 A. Menarini mouse 1:60 2 min pressure cooker 
CK19 Dako mouse 1:50 microwave (Dako Target Retrieval Solution) 
calponin A. Menarini mouse 1:3000 2 min pressure cooker 
caldesmone A. Menarini mouse 1:100 2 min pressure cooker 
SMA Dako mouse 1:150 no pre-treatment 
S100 Dako rabbit 1:2000 5 min chymotrypsin (0.1%, pH 7.8) 
ER Dako mouse 1:60 3 min pressure cooker 
PR Dako mouse 1:100 3 min pressure cooker 
p53 Dako mouse 1:40 2 min pressure cooker 
c-erbB2 Cambridge Bioscience mouse neat 3 min pressure cooker 424 C Jones et al 
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A
Figure 1 Invasive ductal carcinoma with basaloid/myoepithelial cell differentiation, case 5. (A) Haematoxylin and eosin stained, ´ 100; (B) Haematoxylin
and eosin stained, ´ 400 (C) Immunohistochemically stained for cytokeratin 14, ´ 100; (D) Immunohistochemically stained for cytokeratin 19, ´ 100;
(E) Immunohistochemically stained for s100, ´ 200; (F) Immunohistochemically stained for SMA, ´ 200 
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CK14-positive and CK14-negative tumours was significant using
the one-sided t-test (95% confidence level). 
DISCUSSION 
Invasive ductal carcinoma-NST, as determined morphologically,
are thought to arise exclusively from the luminal epithelial cells in
the breast A proportion of these tumours have been demonstrated
to show a basal/myoepithelial cell phenotype by immunohisto-
chemistry (Gusterson et al, 1982; Nagle et al, 1986; Dairkee et al,
1988; Guelstein et al, 1988; Gould et al, 1990; Wetzels et al, 1991;
Malzahn et al, 1998; Tsuda et al, 1999) and patterns of gene
expression (Perou et al, 2000). Here we have reported 7 cases of a
grade III invasive carcinoma (6.6% of the unselected series of
invasive ductal carcinomas) that immunophenotypically were
characterized by positivity with keratin 14 as well as smooth
muscle actin, calponin and caldesmone, all of which are markers
of myoepithelial cells (Foschini et al, 2000). We have adopted the
term of basaloid/myoepithelial cell phenotype for these tumours
by analogy with prostate basal cells that are keratin 14 positive.
Table 3 Clinicopathological and molecular cytogenetic data for the CK14-positive breast tumours. CGH results in italics denote overlaps between CK14
positive and negative areas of the same tumour 
Case Age LN Microscopy Size (cm) Grade CK14 IHC CGH 
1 68 N/A invasive ductal carcinoma 1.6 3 focally positive –17q24-qter, –19, –20p, –Xp22 
focally negative –16p, –17q24-qter, –19, –20p, –22q 
2 44 0/1 invasive ductal carcinoma 1.5 3 diffusely positive +3p24–p25, –16q24, –Xp21–p22 
3 35 1/9 invasive ductal carcinoma 2.5 3 diffusely positive +8p21–p22 +20q12–q13 
4 87 N/A invasive ductal carcinoma 5 3 focally positive –16q, –17q24-qter, –19p 
focally negative +9q 33–q34, –16q, –17q24-qter, –19q, +20, +21q 
5 85 N/A invasive ductal carcinoma 1.7 3 focally positive –11p15, –19q13, –Xp22 
focally negative +8q23–q24, –17q24-qter, –19q13, –20p13, +20q13, –22q, 
6 44 22/25 invasive ductal carcinoma 10 3 diffusely positive –16p13, –16q, –19 
7 46 N/A invasive ductal carcinoma 3.5 3 focally positive –16p, –17p13, –19q
focally negative +7p21–p22–7p36, -8p24-pter, +8q24-qter, –16p,
–17p13, –19q
Table 2 Immunohistochemical findings 
Case CK14 CK19 Calponin Caldesmone SMA S100 ER PR ERBB2 p53 
1* strong strong –ve moderate –ve strong –ve –ve –ve –ve 
10% 100% 50% 25% 
2 strong strong strong weak strong –ve –ve –ve –ve –ve 
50–70% 90–100% 25–50% 75% 75% 
3 strong –ve –ve strong –ve strong –ve –ve –ve –ve 
90–100% 50–75% 75–90% 
4 strong –ve –ve strong –ve strong –ve –ve –ve positive 
10% 75% 90–100%
5 strong strong weak weak strong strong –ve –ve –ve –ve 
10% 50% <10% <10% <10% <10% 
6 strong strong strong weak strong moderate –ve –ve –ve positive 
90–100% 90–100% 25–50% 50% <10% 75% 
7 strong strong strong strong (c) strong strong –ve –ve –ve –ve 
10–20% 50% <10% >75% <10% >90% 
8 –ve strong –ve –ve –ve weak positive positive –ve –ve
90–100% 75%
9 –ve strong not done not done not done not done positive positive positive –ve 
90–100%
10 –ve strong –ve –ve –ve –ve –ve –ve positive positive 
90–100%
11 –ve strong –ve –ve –ve –ve positive positive –ve positive 
90–100%
12 –ve strong –ve –ve –ve –ve positive positive –ve –ve 
90–100%
13 –ve strong –ve –ve –ve strong –ve –ve –ve positive 
90–100% 90–100%
14 –ve strong –ve –ve –ve –ve positive positive –ve –ve 
90–100%
*myosin – weak, 10–20%. 426 C Jones et al 
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Myoepithelial cells both in salivary and breast glands also contain
this specific type of keratin in addition to smooth muscle actin,
calponin and caldesmon. A similar type of lesion had been
reported as poorly differentiated myoepithelial rich carcinomas
(Damiani et al, 1997). 
Previous work in our laboratory has demonstrated a specific
pattern of genetic alterations associated with conventional myoep-
ithelial cell carcinomas, with common losses at 11q, 16p, 16q, 17p,
and 17p part of only a small total number of DNA copy number
changes (Jones et al, 2000). The present invasive ductal carci-
nomas showing a basal/myoepithelial phenotype showed a pat-
tern and number of alterations which was similar to that of pure
myoepithelial carcinomas, but did not show changes commonly
associated with classical ductal carcinomas (losses at 8p and gains
at 8q, 17q, 20q). Some of these tumours also showed areas of focal
CK14-negativity. Such regions showed alterations found in myo-
epithelial carcinomas as well as further alterations, consistent with
CGH data from the literature on invasive ductal breast carcinoma
(Nishizaki et al, 1997; Schwendel et al, 1998; Tirkkonen et al,
1998; Buerger et al, 1999; Roylance et al, 1999) as well as the
present control-matched cases. The overlap in DNA copy number
changes between the CK14-positive and -negative areas from the
same case suggests a possible origin from a common precursor cell
with subsequent divergent differentiation. 
All of the tumours exhibiting a myoepithelial phenotype were
histological grade III, which in is keeping with literature reports of
an association with high grade of malignancy. A recent paper
(Tsuda et al, 2000) highlighted the aggressive nature of tumours
with a myoepithelial phenotype, demonstrating that invasive
ductal carcinomas with a basal phenotype and large, central acel-
lular zones were an indicator of high risk of brain and lung metas-
tases and of death by cancer independent of nodal status and
tumour size. 
The findings that ‘ordinary’ invasive ductal carcinomas-NST
with a basal phenotype behave in a clinically aggressive fashion
(Tsuda et al, 2000) as well as having a specific pattern of genetic
alterations similar to pure myoepithelial carcinomas highlights
the fact that grade III ductal carcinomas contain a subset of
tumours with different biological characteristics and hence
prognosis for the patient. Although we have studied a small
number of samples to date, the lack of ER and PR expression
and p53 positivity in some cases is consistent with this view. It
is interesting that all these high-grade tumours were c-erbB2-
negative. This combination of phenotype (ER, PR, c-erbB2-
negative) is similar to that seen in BRCA1-associated tumours
(Johannsson et al, 1997). The number of cases studied is too
small to make generalizations but clearly warrants further investi-
gation of these interesting subset of grade III ductal carcinomas
These data also indicate that the spectrum of myoepithelial
tumours in the breast is larger than previously appreciated and
includes the subset described here. This will have to be added to
the ‘classical’ range of myoepithelial cell carcinomas (Foschini
and Eusebi, 1998). 
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